Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 248

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 248
---
-budget attainment level (F) | FCF allocation rate      |
| If F is ≤ 70%                             | 0%                       |
| If F is > 70% but < 80%                   | [(F – 70) x 5]%          |
| If F = 80%                                | 50%                      |
| If F is > 80% but < 100%                  | (50 + [(F – 80) x 2.5])% |
| If F = 100%                               | 100%                     |
| If F is > 100% but < 120%                 | F%                       |
| If F is > 120%                            | 120%                     |

• The criterion based on Total Shareholder Return (“TSR”) Rank Improvement accounts for 20% of the award.

| SANOFIFORM 20-F2024 | 145 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

The TSR Rank Improvement corresponds to the change in Sanofi’s TSR rank relative to the TSR of a panel of Sanofi plus 12 peer companies (Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Inc., Eli Lilly and Company Inc., GlaxoSmithKline plc, Johnson & Johnson Inc., Merck Inc., Novartis AG, Novo Nordisk, Pfizer Inc., and Roche Holding Ltd). TSR corresponds to the market performance of Sanofi shares uplifted by dividends per share during the measurement periods, without reinvestment. For the plan applicable to Executive Committee members, the TSR Rank Improvement is determined by comparing the Endpoint Sanofi TSR rank (measured over a three-year period) with the Baseline Sanofi TSR rank (measured over a one-year period). The TSR payment would amount to 50% for an improvement of one place in the rankings, 100% for two places in the rankings, and 150% for three places in the rankings; • The criterion based on CSR accounts for 10% of the award, and is linked to attainment of (i) annual objectives over a three- year period and (ii) a "stretch" objective, linked to the following pillars: 1. Affordable Access: providing essential medicines to non-communicable disease patients through Sanofi Global Health; 2. Planet Care - Carbon Footprint Reduction, scopes 1 & 2 (% CO 2 emissions reduction vs 2019). Attainment of each